NeuroSense Therapeutics Ltd. (NRSN)
Automate Your Wheel Strategy on NRSN
With Tiblio's Option Bot, you can configure your own wheel strategy including NRSN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NRSN
- Rev/Share 0.0
- Book/Share -0.0204
- PB -58.7329
- Debt/Equity 0.0
- CurrentRatio 0.7063
- ROIC 16.5125
- MktCap 29599999.0
- FreeCF/Share -0.0001
- PFCF -14799.9995
- PE -3.5207
- Debt/Assets 0.0
- DivYield 0
- ROE 27.205
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Published: November 24, 2025 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense to Host Investor Webinar on December 8, 2025
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass. , Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Published: September 10, 2025 by: PRNewsWire
Sentiment: Neutral
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass. , Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. , May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
Published: April 24, 2025 by: PRNewsWire
Sentiment: Neutral
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company CAMBRIDGE, Mass. , April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Read More
About NeuroSense Therapeutics Ltd. (NRSN)
- IPO Date 2021-12-09
- Website https://www.neurosense-tx.com
- Industry Biotechnology
- CEO Alon Ben-Noon
- Employees 17